MC
Regulation & Industry121 Assigned Reports
Maya Chen
Regulatory Affairs Correspondent • Senior Regulatory Journalist
Maya covers federal regulatory rulings, FDA Pharmacy Compounding Advisory Committee votes, DOJ/FTC enforcement actions, and international supply chain standards across North American and Pacific biotech sectors.
This is an editorial voice and assignment profile, not a verified individual journalist biography. Published work is attributed to the Peptides Agora Editorial Desk unless a verified human author is named.
Focus Beats:FDA RegulationsPharmacy CompoundingPolicy & LegislationBiotech Supply ChainsCategory 1/2 Reviews
Articles assigned to the Maya Chen voice
Showing 121 reports
peptide-classes•
Cell Penetrating Peptide Database Access and Curated Records
skin-and-cosmetic-peptides•
Hydrolyzed Collagen Vs Collagen Peptides
skin-and-cosmetic-peptides•
NeoCell Bio-Peptides: Trademark Claims and Dietary Supplement Labeling
peptide-classes•
Regulatory Framework for IV Peptide Services at Wellness Clinics
delivery-and-formulation•
Oral Peptide Bioavailability Enhancement Technologies Comparison
skin-and-cosmetic-peptides•
Skin Care Products With Matrixyl 3000
analytical-testing•
Analytical Formulations Inc: Scope and Limits of Peptide Testing
regulation-and-access•
FDA-Approved Peptide Drugs by Indication: A Compliance Registry
general-peptide-topics•
How Long Does It Take for Peptides to Work? The Regulatory Gap Behind Vendor Timelines
general-peptide-topics•
Matrixyl 3000 Regulatory Classification and Cosmetic Formulation Parameters
synthesis-and-manufacturing•
Solid Phase Peptide Synthesis Equipment: Hardware Classifications and Cost Thresholds
definitions-and-types•
Copper Tripeptide-1: What the INCI Record Actually Resolves
definitions-and-types•
Copper Tripeptide & Ectoin Advanced Repair Serum: Formulation and Clinical Claims
general-peptide-topics•
GHK-Cu Loses 503A Category 1 Listing After Withdrawn Nominations
general-peptide-topics•
GLP-1 Receptor Agonists Are Modified Peptides Under FDA Drug Classification
general-peptide-topics•
Lab Rat Peptides: Vendor Entity and Regulatory Status
reference-tables•
Peptide Stacking Chart: Regulatory Status and Evidentiary Limits
proteins-and-polypeptides•
Polypeptide Chains: Structural Definition and Sequence Thresholds
definitions-and-types•
FDA Compounding Review Defines Current Popular Peptide List
general-peptide-topics•
PT-141 Nasal Spray: Regulatory Status and Compounding Distinctions
general-peptide-topics•
Glow Peptide: Regulatory Status of the GHK-Cu, BPC-157, and TB-500 Research Blend
definitions-and-types•
Regulatory Classification of Peptide Types: FDA Approval and Compounding Eligibility
neurotransmitter-inhibitors•
Acetyl Hexapeptide-8 Safety Ceiling and SNARE Inhibition Mechanics Define Cosmetic Utility
collagen-and-bioactive•
Oral Bioactive Peptides for Skin Health Require Verified GI Survival and Trials
collagen-and-bioactive•
Collagen Peptide Bioavailability Is Proven, but Skin Efficacy Depends on Industry Funding
hair-and-follicles•
Copper Tripeptide-1 Hair Loss Evidence Stops at the Petri Dish
cosmetic-peptide-classification•
Cosmetic Peptides Pharmacology: Receptor Mechanisms vs. Clinical Evidence Limits
pigmentation-and-brightening•
Decapeptide-12 Kinetics Define Regulatory Safety Margin Over Hydroquinone
eye-and-microcirculation•
Dipeptide-2 Eye Contour Claims Rest on Proprietary Morphometry, Not Independent Assays
cellular-bioenergetics•
VGVAPG Signaling Mechanics: ERC Binding Kinetics and Fibroblast Chemotaxis
pigmentation-and-brightening•
Nonapeptide-1 Binds MC1R at 40 nM, but Human Efficacy Data Remains Sparse
pigmentation-and-brightening•
Oligopeptide-68 Suppresses MITF Transcription to Treat Melasma Safely
anti-inflammatory-peptides•
Palmitoyl Tetrapeptide-7: IL-6 Suppression Data Defines Cosmetic Boundaries
collagen-and-bioactive•
Tripeptide-29 Mechanisms: In Vitro Collagen Synthesis and MMP Regulation Data
compounding-framework•
503A vs 503B Peptide Compounding: Statutory Limits and Enforcement Realities
amylin-and-combinations•
Cagrilintide Pharmacology Defined by Dual Receptor Agonism and REDEFINE Trial Efficacy
synthesis-and-manufacturing•
FDA Impurity Guidance Forces Re-evaluation of Solid-Phase Peptide Synthesis Protocols
multi-receptor-incretins•
FDA MASH Approval Sets Efficacy Bar for Multi-Receptor Incretin Peptides
quality-and-sourcing•
FDA Warning Letters and Lab Data Define Grey Market Peptide Contamination Risks
analytical-testing•
Reading Peptide COAs: HPLC Purity, Net Content, and Documentation Standards
comparative-longevity•
NAD+ Precursors vs Mitochondrial Peptides: Regulatory and Biochemical Distinctions
formulations-and-delivery•
Oral Peptide Bioavailability Is Defined by 1% Absorption and Strict Dosing Protocols
reconstitution-and-dosing•
Peptide Reconstitution Protocols Depend on Diluent Chemistry and Vial Physics
interactive-reference•
FDA Guidance Forces Peptide Calculator Standards to Address U-100 Measurement Liability
anxiolytic-neuropeptides•
Selank Pharmacology: Russian Clinical Approval Versus U.S. Regulatory Status
cardiolipin-targeting•
FDA Accelerated Approval Defines Elamipretide SS-31 Cardiolipin Pharmacology
dual-agonists-and-nash•
FDA Approval of Semaglutide for MASH Establishes Benchmark for Dual Agonist Development
anti-doping-standards•
FDA Warning Letters and WADA S0 Sanctions Converge on Unapproved Peptides
approval-and-legality•
Are Peptides Legal? FDA Tiers, Compounding Bans, and the 2026 Regulatory Gap
proteins-and-polypeptides•
Protein Sequence as Regulatory Proof: Why Amino Acid Identity Drives Compliance
approval-and-legality•
FDA-Approved Peptides: What Approval Actually Means
structure-and-sequences•
